NMN vs NR: What Human Trials Actually Show

Two molecules, one job, and a lot of marketing

If you have typed "NMN vs NR" into a search bar, you were probably looking for a winner. We are going to disappoint you slightly and then be useful: on the evidence available, there is no winner. There is a difference in how much randomised human data sits behind each molecule, and that difference is worth understanding before you spend $40 a month.

Worth noting, since we work from search data: a real share of shoppers type NDA supplement or NMM into Amazon. Those are misspellings of NAD and NMN, they appear thousands of times a month, and no honest review will pretend they mean something else.

What each molecule actually is

NR — nicotinamide riboside

NR is a nucleoside: a nicotinamide ring attached to a ribose sugar. It is small, water-soluble, and — critically for product design — it enters cells and feeds the salvage pathway. The commercially standardized form is nicotinamide riboside chloride, which is the version used in most published trials [1][2].

NMN — nicotinamide mononucleotide

NMN is one step further along the same pathway: NR plus a phosphate group. It is a nucleotide rather than a nucleoside. In rodent work it is absorbed and converted efficiently; the human data is younger and thinner, which is a statement about study volume, not about inferiority [9].

NMNH and NADH — the newer labels

Two names you will increasingly see on labels are NMNH (reduced NMN) and NADH (reduced NAD). Both are chemically distinct from NAD+ itself. NADH is an electron carrier — it is the reduced form that donates electrons in energy-yielding metabolism — and NMNH is a reduced variant of NMN. Both have far less human trial data than either NR or NMN, so treat confident claims about them as positioning rather than evidence.

The absorption question nobody wants to answer directly

NAD+ is a charged dinucleotide. Swallow it and most of it is broken down in the gut before it ever reaches your bloodstream intact. That is why a product labeled purely as an NAD+ supplement is, in practice, almost always delivering a precursor — and why the honest framing is "precursor converts toward NAD+," not "NAD+ enters your cells."

Do sublingual, liposomal and liquid forms change that?

Potentially, marginally, and not in a way anyone has proven. Liposomal encapsulation is a real pharmaceutical strategy for improving delivery of fragile molecules, and sublingual absorption bypasses first-pass metabolism for some small molecules [7]. But no head-to-head human trial has shown that a liposomal or sublingual NAD+ precursor produces a better clinical outcome than a well-dosed capsule. Liquid formulas are convenient and pleasant to take; that is a real benefit and it is not the same claim as superior absorption.

What the human trials show — side by side

Here is the record, with the doses actually used.

Read the "Result" column slowly. Every one of these trials found that the precursor was safe. Every one that measured NAD+ found it went up. And almost every trial that measured a clinical endpoint found it did not move [11].

The honest scorecard

• Depth of human record: NR. More randomised trials, more dose-response work, longer safety follow-up.
• Recent momentum: NMN. Several dose-dependent trials published since 2020, largely in healthy middle-aged adults.
• Biomarker effect: comparable. Both raise circulating NAD+ markers. Neither has been shown to do it better than the other head-to-head in humans.
• Clinical outcomes: a tie at zero. Neither precursor has completed a large randomised trial with a hard clinical endpoint, and a 2026 systematic review pooling 113 intervention studies found a reliable biomarker increase without a consistent clinical benefit [11].

That is the whole comparison. Anything beyond it — "NMN is the newer generation," "NR is obsolete," "one of them actually reverses aging" — is marketing wearing the clothes of science.

A regulatory footnote that affects what you can buy

NMN spent three years in a regulatory grey zone in the United States. In November 2022 the FDA concluded it was excluded from the dietary supplement definition; after a citizen petition from industry groups, that position was reversed on September 29, 2025, and formally confirmed in a letter dated December 2, 2025. NMN is now back on the market, but it remains subject to new dietary ingredient requirements — a company selling it is expected to have a notification on file. NR never left, which is part of why its commercial and clinical record is longer.

What to do about it

1. Pick one precursor and dose it properly. The trials with the strongest data used a single clearly named precursor at a stated milligram amount. A blend total tells you nothing about how much of the active you are getting.
2. Ignore the delivery-format war. Liposomal, sublingual, powder or liquid capsules — choose the one you will actually take daily. Adherence beats packaging.
3. Ask for the certificate of analysis. Third-party tested is a claim; a COA is a document. Any serious brand publishes it.
4. Give it a defined trial period and judge honestly. If you take a NAD+ booster for eight weeks and notice nothing, that is consistent with the trial data — it is not evidence you picked the wrong molecule.

When this is not a nutrition question

Nothing in this article is a reason to delay medical care. Persistent fatigue, unexplained weight loss, or a sleep problem lasting more than a few weeks should be evaluated by a clinician rather than supplemented around. If you are pregnant, nursing, or taking prescription medication, talk to your healthcare provider before starting any supplement. Supplements are not a substitute for diagnosis or for treating a condition.

Why we chose NR for our NAD+ formula

Fmlave NAD+ 120 capsules delivers 500mg of nicotinamide riboside per serving. We picked NR over NMN for one unglamorous reason: at the time of formulation it had the deeper published human trial record, including dose-response data on whole-blood NAD+ [1][2]. If that comparison changes, the honest answer may change with it — and we would rather say that than pretend the science is settled.

The 500 mg dose sits inside the range used in published human trials. It is a 12-in-1 complex that also includes resveratrol, quercetin, fisetin and a 30:1 shilajit extract, in 120 vegan capsules — a 60-day supply at two capsules daily. Third-party tested, non-GMO, and free of gluten and soy. It is a precursor, not a miracle: the formulation supplies raw material to a pathway, and the pathway still depends on sleep, training and inflammation load.